{
  "company": "Revvity",
  "ticker": "RVTY",
  "period": {
    "from": "2026-03-16",
    "to": "2026-04-15",
    "days": 30
  },
  "sentiment_breakdown": {
    "positive": 22,
    "negative": 17,
    "neutral": 38
  },
  "synthesis": {
    "executive_summary": "Sentiment analysis for Revvity (RVTY) from 2026-03-16 to 2026-04-15. Analyzed 77 items across FDA and news sources.",
    "key_findings": [],
    "overall_sentiment": "neutral"
  },
  "top_positive": [
    {
      "title": "Nephron Research gets more bullish on Revvity, upgrades shares",
      "date": "2026-03-26",
      "source": "news",
      "score": 0.991
    },
    {
      "title": "[Latest] Global Environmental Mass Spectrometry Market Size/Share Worth USD 6.47 Billion by 2035 at a 7.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
      "date": "2026-04-02",
      "source": "news",
      "score": 0.859
    },
    {
      "title": "Catabolism of extracellular glutathione supplies cysteine to support tumours",
      "date": "2026-03-18",
      "source": "news",
      "score": 0.856
    },
    {
      "title": "Revvity Inc. stock outperforms competitors on strong trading day",
      "date": "2026-04-08",
      "source": "alpha_vantage",
      "score": 0.711
    },
    {
      "title": "Revvity Inc. stock outperforms competitors on strong trading day",
      "date": "2026-04-02",
      "source": "alpha_vantage",
      "score": 0.711
    },
    {
      "title": "Revvity Gains on Diagnostics Strength, Faces China Headwinds",
      "date": "2026-04-06",
      "source": "alpha_vantage",
      "score": 0.681
    },
    {
      "title": "Allergy Diagnostic Market by Product & Service, Test Type, Allergen, End User - Global Forecast to 2031",
      "date": "2026-04-13",
      "source": "news",
      "score": 0.602
    },
    {
      "title": "Global Next-Generation Sequencing (NGS) Market to Double in Size by 2030 - Asia-Pacific NGS Market Poised for Fastest Growth, Driven by Large-Scale Genomic Projects and the Rising Need for Precision Medicine",
      "date": "2026-04-10",
      "source": "news",
      "score": 0.557
    },
    {
      "title": "Revvity (RVTY) Valuation Check After Recent Share Price Gains And Mixed Longer Term Returns",
      "date": "2026-04-03",
      "source": "alpha_vantage",
      "score": 0.557
    },
    {
      "title": "Machine says go, doctor says no: an ecological momentary assessment analysis examining clinicians' perceptions of, and their antibiotic prescribing behaviour when using rapid molecular diagnostic tests in intensive care.",
      "date": "2026 Mar 2",
      "source": "pubmed",
      "score": 0.494
    }
  ],
  "top_negative": [
    {
      "title": "The E3 ubiquitin ligase mechanism specifying targeted microRNA degradation",
      "date": "2026-03-18",
      "source": "news",
      "score": -0.778
    },
    {
      "title": "Ectopic NMDAR expression in cancer unmasks germline-encoded autoimmunity",
      "date": "2026-03-25",
      "source": "news",
      "score": -0.66
    },
    {
      "title": "Feasibility of deep learning-based cancer detection in ultrasound microvascular images.",
      "date": "2026-04-15",
      "source": "pubmed",
      "score": -0.66
    },
    {
      "title": "A µ-opioid receptor superagonist analgesic with minimal adverse effects",
      "date": "2026-04-01",
      "source": "news",
      "score": -0.612
    },
    {
      "title": "Revvity downgraded to Equal Weight from Overweight at Barclays",
      "date": "2026-04-14",
      "source": "alpha_vantage",
      "score": -0.561
    },
    {
      "title": "Barclays Downgrades Revvity to Equalweight From Overweight, Adjusts Price Target to $95 From $118",
      "date": "2026-04-14",
      "source": "alpha_vantage",
      "score": -0.561
    },
    {
      "title": "Barclays Downgrades Revvity(RVTY.US) to Hold Rating, Cuts Target Price to $95",
      "date": "2026-04-14",
      "source": "alpha_vantage",
      "score": -0.496
    },
    {
      "title": "Revvity Inc. stock underperforms Monday when compared to competitors despite daily gains",
      "date": "2026-04-13",
      "source": "alpha_vantage",
      "score": -0.458
    },
    {
      "title": "Neonatal hypoglycaemic brain injury, a common cause of early-childhood epilepsy in India: A prospective longitudinal study on aetiologies and outcomes.",
      "date": "2026-04-15",
      "source": "pubmed",
      "score": -0.421
    },
    {
      "title": "Evercore Maintains Revvity(RVTY.US) With Buy Rating, Cuts Target Price to $108",
      "date": "2026-04-06",
      "source": "alpha_vantage",
      "score": -0.296
    }
  ],
  "raw_data": {
    "total_items": 77,
    "items": [
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Allergy Diagnostic Market by Product & Service, Test Type, Allergen, End User - Global Forecast to 2031",
        "description": "The allergy diagnostic market is set to surge, projected to reach USD 10.77 billion by 2030 from USD 6.80 billion in 2025, at a CAGR of 9.6%. Technological innovation in diagnostics, such as multiplex immunoassays and molecular allergology, drives this growth…",
        "url": "https://www.globenewswire.com/news-release/2026/04/13/3272461/28124/en/Allergy-Diagnostic-Market-by-Product-Service-Test-Type-Allergen-End-User-Global-Forecast-to-2031.html",
        "date": "2026-04-13",
        "published_at": "2026-04-13T12:00:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.602,
          "confidence": 0.6
        }
      },
      {
        "source": "news",
        "source_name": "Barchart.com",
        "title": "What to Expect From Revvity's Next Quarterly Earnings Report",
        "description": "Revvity will release its first-quarter earnings soon, and analysts anticipate a low single-digit bottom-line growth.",
        "url": "https://www.barchart.com/story/news/1264071/what-to-expect-from-revvity-s-next-quarterly-earnings-report",
        "date": "2026-04-12",
        "published_at": "2026-04-12T15:49:34Z",
        "sentiment": {
          "label": "positive",
          "score": 0.128,
          "confidence": 0.13
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Global Next-Generation Sequencing (NGS) Market to Double in Size by 2030 - Asia-Pacific NGS Market Poised for Fastest Growth, Driven by Large-Scale Genomic Projects and the Rising Need for Precision Medicine",
        "description": "Dublin, April 10, 2026 (GLOBE NEWSWIRE) -- The \"Next-Generation Sequencing Market by Product Type, Technology, Workflow, Services, Application - Global Forecast to 2030\" has been added to ResearchAndMarkets.com's offering.The next-generation sequencing (NGS) …",
        "url": "https://www.globenewswire.com/news-release/2026/04/10/3271604/28124/en/Global-Next-Generation-Sequencing-NGS-Market-to-Double-in-Size-by-2030-Asia-Pacific-NGS-Market-Poised-for-Fastest-Growth-Driven-by-Large-Scale-Genomic-Projects-and-the-Rising-Need-.html",
        "date": "2026-04-10",
        "published_at": "2026-04-10T09:45:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.557,
          "confidence": 0.56
        }
      },
      {
        "source": "news",
        "source_name": "Nature.com",
        "title": "Synthetic super-enhancers enable precision viral immunotherapy",
        "description": "Synthetic super-enhancers enable specific delivery of anticancer payloads, achieving tumour elimination after a single dose in a mouse model of aggressive glioblastoma.",
        "url": "https://www.nature.com/articles/s41586-026-10329-6",
        "date": "2026-04-08",
        "published_at": "2026-04-08T00:00:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.153,
          "confidence": 0.15
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Global DNA Read, Write and Edit Market to Surge to $67.7 Billion by 2030, Driven by CRISPR Advances, Genomic Diagnostics and Expanding Clinical Applications",
        "description": "Rapid expansion in clinical applications, rising demand for genomic diagnostics, and increased investment in CRISPR-based therapeutics are fueling demand....",
        "url": "https://www.globenewswire.com/news-release/2026/04/07/3269543/0/en/Global-DNA-Read-Write-and-Edit-Market-to-Surge-to-67-7-Billion-by-2030-Driven-by-CRISPR-Advances-Genomic-Diagnostics-and-Expanding-Clinical-Applications.html",
        "date": "2026-04-07",
        "published_at": "2026-04-07T17:44:00Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.026,
          "confidence": 0.03
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "[Latest] Global Environmental Mass Spectrometry Market Size/Share Worth USD 6.47 Billion by 2035 at a 7.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
        "description": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Environmental Mass Spectrometry Market size & share revenue was valued at approximately USD 2.84 Billion in 2025 and is expected…",
        "url": "https://www.globenewswire.com/news-release/2026/04/02/3267246/0/en/Latest-Global-Environmental-Mass-Spectrometry-Market-Size-Share-Worth-USD-6-47-Billion-by-2035-at-a-7-6-CAGR-Custom-Market-Insights-Analysis-Outlook-Leaders-Report-Trends-Forecast-.html",
        "date": "2026-04-02",
        "published_at": "2026-04-02T11:30:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.859,
          "confidence": 0.86
        }
      },
      {
        "source": "news",
        "source_name": "Yahoo Entertainment",
        "title": "Here’s Artisan Mid Cap Value Fund’s Investment Thesis for Revvity (RVTY)",
        "description": "",
        "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_c5216dc8-8c36-4957-a877-72cca4ac0804",
        "date": "2026-04-01",
        "published_at": "2026-04-01T15:04:29Z",
        "sentiment": {
          "label": "positive",
          "score": 0.34,
          "confidence": 0.34
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Protein Chip Market Size is Expected to Reach USD 4.79 Billion by 2035 Owing to the Rapid Adoption of Mass-screening Proteomics Technologies Globally | SNS Insider",
        "description": "Protein chip market grows to USD 4.79 Billion by 2035 at 6.89% CAGR, driven by proteomics research, and rising clinical diagnostics adoption....",
        "url": "https://www.globenewswire.com/news-release/2026/04/01/3266380/0/en/Protein-Chip-Market-Size-is-Expected-to-Reach-USD-4-79-Billion-by-2035-Owing-to-the-Rapid-Adoption-of-Mass-screening-Proteomics-Technologies-Globally-SNS-Insider.html",
        "date": "2026-04-01",
        "published_at": "2026-04-01T09:30:00Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.026,
          "confidence": 0.03
        }
      },
      {
        "source": "news",
        "source_name": "Nature.com",
        "title": "A µ-opioid receptor superagonist analgesic with minimal adverse effects",
        "description": "N-desethyl-fluornitrazene is a µ-opioid receptor agonist derived from nitazenes that has supramaximal intrinsic efficacy that produces analgesia with minimal adverse effects in rodent models.",
        "url": "https://www.nature.com/articles/s41586-026-10299-9",
        "date": "2026-04-01",
        "published_at": "2026-04-01T00:00:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.612,
          "confidence": 0.61
        }
      },
      {
        "source": "news",
        "source_name": "Nature.com",
        "title": "Mosaic gastruloids reveal a temporal restriction for developmental cell competition",
        "description": "Frenster et al. utilize mosaic mouse gastruloids as a model of cell fitness and competition, identifying a temporal window between primed pluripotency and early gastrulation during which cell competition occurs in mammalian embryogenesis.",
        "url": "https://www.nature.com/articles/s41556-026-01923-x",
        "date": "2026-04-01",
        "published_at": "2026-04-01T00:00:00Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Yahoo Entertainment",
        "title": "Stifel Maintains a Hold Rating on Revvity (RVTY)",
        "description": "",
        "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_5264e652-64a8-4995-bdc5-fa1ad7e19dbd",
        "date": "2026-03-27",
        "published_at": "2026-03-27T07:29:27Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Thefly.com",
        "title": "Nephron Research gets more bullish on Revvity, upgrades shares",
        "description": "See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual investors, professional money managers, active traders, and corpor…",
        "url": "https://www.thefly.com/RVTY",
        "date": "2026-03-26",
        "published_at": "2026-03-26T11:13:51Z",
        "sentiment": {
          "label": "positive",
          "score": 0.991,
          "confidence": 0.99
        }
      },
      {
        "source": "news",
        "source_name": "Nature.com",
        "title": "Ectopic NMDAR expression in cancer unmasks germline-encoded autoimmunity",
        "description": "NMDAR expression is sufficient to induce B cell recruitment and affinity maturation, resulting in receptor-modulating antibodies that connect anti-cancer immunity and autoimmunity.",
        "url": "https://www.nature.com/articles/s41586-026-10278-0",
        "date": "2026-03-25",
        "published_at": "2026-03-25T00:00:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "news",
        "source_name": "Yahoo Entertainment",
        "title": "Is Revvity Stock Underperforming the S&P 500?",
        "description": "",
        "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_0da74d95-ac07-4f8b-a52f-bf2fc7eb9b22",
        "date": "2026-03-20",
        "published_at": "2026-03-20T10:12:04Z",
        "sentiment": {
          "label": "negative",
          "score": -0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Genomics Market to Reach USD 85.09 Billion by 2030 | MarketsandMarkets™",
        "description": "Advancements in NGS, AI-driven bioinformatics, and expanding precision medicine initiatives are positioning genomics as a strategic pillar in modern healthcare, diagnostics, and drug discovery. Advancements in NGS, AI-driven bioinformatics, and expanding prec…",
        "url": "https://www.globenewswire.com/news-release/2026/03/19/3259211/0/en/Genomics-Market-to-Reach-USD-85-09-Billion-by-2030-MarketsandMarkets.html",
        "date": "2026-03-19",
        "published_at": "2026-03-19T14:30:00Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.026,
          "confidence": 0.03
        }
      },
      {
        "source": "news",
        "source_name": "Nature.com",
        "title": "Catabolism of extracellular glutathione supplies cysteine to support tumours",
        "description": "Catabolism of extracellular glutathione by γ-glutamyltransferases supports tumour growth and survival, and pharmacological targeting of these enzymes slows tumour growth.",
        "url": "https://www.nature.com/articles/s41586-026-10268-2",
        "date": "2026-03-18",
        "published_at": "2026-03-18T00:00:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.856,
          "confidence": 0.86
        }
      },
      {
        "source": "news",
        "source_name": "Nature.com",
        "title": "The E3 ubiquitin ligase mechanism specifying targeted microRNA degradation",
        "description": "Target-directed microRNA degradation is driven by the atypical ZSWIM8–CUL3 E3 ubiquitin ligase that uses a two-RNA-factor authentication mechanism to specifically recognize AGO–miRNA–trigger RNA complexes and polyubiquitylate AGO.",
        "url": "https://www.nature.com/articles/s41586-026-10232-0",
        "date": "2026-03-18",
        "published_at": "2026-03-18T00:00:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.778,
          "confidence": 0.78
        }
      },
      {
        "source": "news",
        "source_name": "Yahoo Entertainment",
        "title": "Emerald Growth Equity Strategy Sold Revvity (RVTY) in Q4",
        "description": "",
        "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_649a11d8-8503-4978-8942-c9108f173957",
        "date": "2026-03-16",
        "published_at": "2026-03-16T13:58:38Z",
        "sentiment": {
          "label": "positive",
          "score": 0.382,
          "confidence": 0.38
        }
      },
      {
        "source": "pubmed",
        "pmid": "41974962",
        "title": "The dual role of TOX in regulating T(H)1 and CD8(+) T cell fate.",
        "authors": "Kye YC et al.",
        "journal": "Nature immunology",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41974962/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41927314",
        "title": "Implementing shorter all-oral treatment durations for multidrug-resistant tuberculosis in the UK: from concept to application.",
        "authors": "Chavda A et al.",
        "journal": "BMJ open respiratory research",
        "date": "2026 Apr 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41927314/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41877199",
        "title": "Machine says go, doctor says no: an ecological momentary assessment analysis examining clinicians' perceptions of, and their antibiotic prescribing behaviour when using rapid molecular diagnostic tests in intensive care.",
        "authors": "Stewart SF et al.",
        "journal": "Antimicrobial resistance and infection control",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41877199/",
        "sentiment": {
          "label": "positive",
          "score": 0.494,
          "confidence": 0.49
        }
      },
      {
        "source": "pubmed",
        "pmid": "41858248",
        "title": "Prevalence and Predictors of Tuberculosis in Adults and Adolescents With Sputum Trace Ultra Results in 2 High-Burden Clinical Settings.",
        "authors": "Visek C et al.",
        "journal": "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41858248/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41831164",
        "title": "PDXK Mutation Causes a Late-Onset Pyridoxal 5'-Phosphate-Responsive Peripheral Neuropathy Preceded by Neonatal Seizures: Authors' Reply.",
        "authors": "Arora A et al.",
        "journal": "Indian journal of pediatrics",
        "date": "2026-04-15",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41831164/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41774927",
        "title": "Measuring the Degree of Labeling of Antibody-Dye Conjugates with a Single-Molecule-Sensitive Digital Flow Cytometer.",
        "authors": "Cheng Y et al.",
        "journal": "Analytical chemistry",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41774927/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41270708",
        "title": "Feasibility of deep learning-based cancer detection in ultrasound microvascular images.",
        "authors": "Bautista KJB et al.",
        "journal": "Ultrasonics",
        "date": "2026-04-15",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41270708/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41091569",
        "title": "Cannabis Provenance by Isotope Ratio Analysis.",
        "authors": "Filer CN",
        "journal": "Cannabis and cannabinoid research",
        "date": "2026-04-15",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41091569/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "40814143",
        "title": "Neonatal hypoglycaemic brain injury, a common cause of early-childhood epilepsy in India: A prospective longitudinal study on aetiologies and outcomes.",
        "authors": "Gupta C et al.",
        "journal": "Developmental medicine and child neurology",
        "date": "2026-04-15",
        "url": "https://pubmed.ncbi.nlm.nih.gov/40814143/",
        "sentiment": {
          "label": "negative",
          "score": -0.421,
          "confidence": 0.42
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Barclays Downgrades Revvity(RVTY.US) to Hold Rating, Cuts Target Price to $95",
        "url": "https://www.moomoo.com/news/post/68285960/barclays-downgrades-revvity-rvtyus-to-hold-rating-cuts-target-price",
        "date": "2026-04-14",
        "summary": "Barclays has downgraded Revvity (RVTY.US) from an Overweight to a Hold rating. The investment bank also lowered its target price for Revvity shares to $95. This revised outlook suggests a more cautious stance on the company's stock by Barclays analysts.",
        "sentiment_score": -0.649683,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.496,
          "confidence": 0.5
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Is Revvity (RVTY) Starting To Look Attractive After Recent Share Price Weakness",
        "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rvty/revvity/news/is-revvity-rvty-starting-to-look-attractive-after-recent-sha",
        "date": "2026-04-14",
        "summary": "Revvity (RVTY) has seen recent share price weakness, with a 5.6% decline year-to-date and a 4.8% decline over the past year. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 31.1% at its current price of US$92.64, indicating a fair value of around $134.50 per share. However, its Price/Earnings ratio of 43.18x is above the industry average and its estimated \"Fair Ratio\" of 22.44x, suggesting it is overvalued from an earnings perspective.",
        "sentiment_score": 0.267993,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.318,
          "confidence": 0.32
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Revvity downgraded to Equal Weight from Overweight at Barclays",
        "url": "https://www.tipranks.com/news/the-fly/revvity-downgraded-to-equal-weight-from-overweight-at-barclays-thefly-news",
        "date": "2026-04-14",
        "summary": "Barclays analyst Luke Sergott downgraded Revvity (RVTY) to Equal Weight from Overweight, lowering the price target to $95 from $118. The downgrade is attributed to potential margin risk ahead of the company's Q1 report and competitive threats in flow cytometry reagents from Waters. Although flow reagents represent a small portion of Revvity's overall revenue, they are crucial for the company to achieve its growth targets.",
        "sentiment_score": -0.439182,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.561,
          "confidence": 0.56
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Barclays Downgrades Revvity to Equalweight From Overweight, Adjusts Price Target to $95 From $118",
        "url": "https://www.marketscreener.com/news/barclays-downgrades-revvity-to-equalweight-from-overweight-adjusts-price-target-to-95-from-118-ce7e50dfdb8bf126",
        "date": "2026-04-14",
        "summary": "Barclays has downgraded Revvity (RVTY) from Overweight to Equalweight, simultaneously lowering its price target from $118 to $95. This adjustment reflects a more cautious outlook on the company's stock performance. The article also mentions recent price target adjustments from other financial institutions like Goldman Sachs and TD Cowen.",
        "sentiment_score": -0.405788,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.561,
          "confidence": 0.56
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Revvity Q1 2026 Earnings Forecast & Stock Analysis | Barchart Report - News and Statistics",
        "url": "https://www.indexbox.io/blog/revvity-q1-2026-earnings-preview-analysts-project-102-eps/",
        "date": "2026-04-13",
        "summary": "Analysts project Revvity will report $1.02 EPS for Q1 2026, marking a slight increase year-over-year, with the company consistently exceeding Wall Street estimates in its recent quarterly reports. Despite this, Revvity's stock has declined over the past year, attributed to concerns over new international trade policies, contrasting with gains in the broader market and healthcare sector. The overall analyst consensus is moderately positive, recommending buying or holding, with an average price ta",
        "sentiment_score": 0.251953,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Revvity Inc. stock underperforms Monday when compared to competitors despite daily gains",
        "url": "https://www.marketwatch.com/data-news/revvity-inc-stock-underperforms-monday-when-compared-to-competitors-despite-daily-gains-e8579041-603c3530b2c4?mod=mw_quote_news",
        "date": "2026-04-13",
        "summary": "Revvity Inc. (RVTY) stock saw a gain of 3.17% on Monday, closing at $92.64, yet still underperformed against the broader market indices like the S&P 500 Index and the Dow Jones Industrial Average. The company's stock remains significantly below its 52-week high of $118.30.",
        "sentiment_score": 0.007731,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.458,
          "confidence": 0.46
        }
      },
      {
        "source": "alpha_vantage",
        "title": "RVTY Unveils Signals BioDesign for Faster Molecular Cloning & R&D Data",
        "url": "https://finance.yahoo.com/sectors/healthcare/articles/rvty-unveils-signals-biodesign-faster-145800155.html",
        "date": "2026-04-13",
        "summary": "Revvity, Inc. (RVTY) has launched Signals BioDesign, a cloud-based molecular cloning platform aimed at speeding up R&D in biotech and pharmaceuticals. This new platform, part of Revvity Signals Software, is designed to simplify complex cloning workflows and enhance collaboration, especially crucial for developing next-generation therapies. Despite a recent slight dip in stock performance, the company anticipates long-term growth by addressing critical needs in biologics research and integrating ",
        "sentiment_score": 0.468525,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Keys to Succeed in the Booming $300 Million Optical Genome Mapping Market 2026-2030: Bionano Genomics, 10x Genomics, and Oxford Nanopore Technologies Lead",
        "url": "https://www.globenewswire.com/news-release/2026/04/13/3272643/28124/en/Keys-to-Succeed-in-the-Booming-300-Million-Optical-Genome-Mapping-Market-2026-2030-Bionano-Genomics-10x-Genomics-and-Oxford-Nanopore-Technologies-Lead.html",
        "date": "2026-04-13",
        "summary": "The optical genome mapping (OGM) market is projected to grow significantly from $0.23 billion in 2025 to $0.74 billion by 2030, driven by the limitations of next-generation sequencing in detecting large structural variants, increased genomic research funding, and rising prevalence of genetic disorders. Key trends include OGM's adoption for structural variant detection in rare diseases and cancer, its use in clinical diagnostics, and the growing demand for precision medicine. Major players like B",
        "sentiment_score": 0.274811,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 0.736211,
        "sentiment": {
          "label": "positive",
          "score": 0.494,
          "confidence": 0.49
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Goldman Sachs Adjusts Price Target on Revvity to $95 From $110, Maintains Neutral Rating",
        "url": "https://www.moomoo.com/news/post/68235392/goldman-sachs-adjusts-price-target-on-revvity-to-95-from",
        "date": "2026-04-13",
        "summary": "Goldman Sachs has revised its price target for Revvity (NYSE: RVTY) to $95, down from the previous $110. Despite this reduction, the firm has decided to maintain a Neutral rating on the stock. This adjustment reflects a moderated outlook from the investment bank regarding Revvity's stock performance.",
        "sentiment_score": -0.285913,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "RVTY Unveils Signals BioDesign for Faster Molecular Cloning & R&D Data",
        "url": "https://www.tradingview.com/news/zacks:f59e954f6094b:0-rvty-unveils-signals-biodesign-for-faster-molecular-cloning-r-d-data/",
        "date": "2026-04-13",
        "summary": "Revvity, Inc. (RVTY) has launched Signals BioDesign, a new cloud-based molecular cloning platform through its Revvity Signals Software division. This platform aims to simplify complex cloning workflows for biotech and pharmaceutical R&D teams, enabling faster development of therapies. The move strengthens Revvity's software portfolio and positions it for future growth in predictive biology, especially as the molecular cloning market is projected to reach $6 billion in 2026.",
        "sentiment_score": 0.348167,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Revvity to Hold Earnings Call on Tuesday, May 5, 2026",
        "url": "https://www.marketscreener.com/news/revvity-to-hold-earnings-call-on-tuesday-may-5-2026-ce7e50dedb81f020",
        "date": "2026-04-13",
        "summary": "Revvity, Inc. (NYSE: RVTY) announced it will release its first quarter 2026 financial results before market open on Tuesday, May 5, 2026. The company will host a conference call on the same day at 7:30 a.m. ET to discuss these results, featuring President and CEO Prahlad Singh and CFO Max Krakowiak. A live audio webcast will be accessible on the Investors section of Revvity's website.",
        "sentiment_score": 0.128227,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Revvity launches Signals BioDesign to advance biologic research workflows",
        "url": "https://www.selectscience.net/article/revvity-launches-signals-biodesign-to-advance-biologic-research-workflows",
        "date": "2026-04-13",
        "summary": "Revvity Inc. has launched Signals BioDesign, a cloud-native molecular cloning solution designed to streamline biologics research workflows. This platform enables high-throughput construct design (up to 1,000 constructs) with real-time data sharing and enterprise-grade collaboration for biotech and pharma R&D teams. Signals BioDesign integrates with the Signals One™ platform, positioning research teams for future machine learning applications in sequence optimization and predictive design.",
        "sentiment_score": 0.496044,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "How Investors Are Reacting To AbCellera Biologics (ABCL) After New Jones Trading Coverage Initiation",
        "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/how-investors-are-reacting-to-abcellera-biologics-abcl-after",
        "date": "2026-04-13",
        "summary": "Jones Trading recently initiated coverage on AbCellera Biologics (ABCL), assigning a new rating and highlighting its antibody-medicine pipeline, which has renewed focus on the company's transition to clinical-stage programs. While this attention may boost interest in upcoming clinical data from programs like ABCL635, the core investment narrative remains centered on the company's ability to translate its discovery engine into successful clinical assets, despite ongoing risks such as losses and h",
        "sentiment_score": 0.158675,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 0.616524,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Revvity’s IGRA Growth Engine Faces Crucial Test—Can It Offset Eroding China and Immunodiagnostics Headwinds?",
        "url": "https://www.bitget.com/amp/news/detail/12560605360628",
        "date": "2026-04-12",
        "summary": "Revvity (RVTY) faces a critical juncture where its growth in Interferon-Gamma Release Assay (IGRA) testing needs to overcome significant headwinds from declining revenues in China and the Immunodiagnostics segment. While the market anticipates a strong earnings report, much of the positive news is already priced into the stock, suggesting limited upside unless the company provides exceptionally robust forward-looking guidance. The upcoming earnings call will focus on the pace of IGRA adoption an",
        "sentiment_score": -0.115321,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.382,
          "confidence": 0.38
        }
      },
      {
        "source": "alpha_vantage",
        "title": "What to Expect From Revvity's Next Quarterly Earnings Report",
        "url": "https://www.inkl.com/news/what-to-expect-from-revvity-s-next-quarterly-earnings-report",
        "date": "2026-04-12",
        "summary": "Revvity, Inc. (RVTY) is preparing to announce its fiscal first-quarter earnings for 2026, with analysts anticipating a 1% increase in EPS to $1.02. Despite consistent outperformance in past EPS estimates, RVTY's stock has underperformed the S&P 500 and the Health Care Select Sector SPDR ETF over the last year, partly due to concerns over new global tariffs. Analysts hold a \"Moderate Buy\" consensus rating for RVTY, with an average price target suggesting a 31.6% potential upside.",
        "sentiment_score": 0.215861,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "What to Expect From Revvity's Next Quarterly Earnings Report",
        "url": "https://www.barchart.com/story/news/1264071/what-to-expect-from-revvity-s-next-quarterly-earnings-report",
        "date": "2026-04-12",
        "summary": "Revvity, Inc. (RVTY) is a health sciences solutions provider valued at $10 billion. The company is expected to announce its fiscal first-quarter earnings for 2026 soon, with analysts projecting a diluted EPS of $1.02, a 1% increase year-over-year. Despite consistent EPS beats, RVTY stock has underperformed the S&P 500 and the Health Care Select Sector SPDR ETF in the past year, partly due to fears surrounding new global tariffs.",
        "sentiment_score": 0.021642,
        "sentiment_label": "Neutral",
        "relevance_score": 0.309609,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "What to Expect From Revvity's Next Quarterly Earnings Report",
        "url": "https://www.financialcontent.com/article/barchart-2026-4-12-what-to-expect-from-revvitys-next-quarterly-earnings-report",
        "date": "2026-04-12",
        "summary": "Revvity, Inc. (RVTY) is expected to announce its fiscal first-quarter earnings for 2026, with analysts anticipating a profit of $1.02 per share. Despite the company consistently surpassing EPS estimates, its stock has underperformed the S&P 500 and the Health Care Select Sector SPDR ETF due to concerns over new global tariffs. Analysts currently have a \"Moderate Buy\" rating on RVTY, with an average price target indicating a significant potential upside.",
        "sentiment_score": 0.220497,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "(RVTY) Movement as an Input in Quant Signal Sets",
        "url": "https://news.stocktradersdaily.com/news_release/35/RVTY_Movement_as_an_Input_in_Quant_Signal_Sets_041226095401_1776002041.html",
        "date": "2026-04-12",
        "summary": "This article analyzes Revvity Inc. (NASDAQ: RVTY) using AI models to generate trading strategies and signals. It highlights strong near and mid-term sentiment, an exceptional risk-reward setup, and provides specific entry, target, and stop-loss zones for position, momentum breakout, and risk hedging strategies across multiple timeframes.",
        "sentiment_score": 0.418355,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "ZoomInfo Technologies Receives 'Hold' Rating from Analysts",
        "url": "https://nationaltoday.com/us/ma/waltham/news/2026/04/12/zoominfo-technologies-receives-hold-rating-from-analysts-1/",
        "date": "2026-04-12",
        "summary": "ZoomInfo Technologies (NASDAQ:GTM) has received a consensus 'Hold' rating from analysts, with a mixed outlook on its growth prospects and competitive position. The stock has seen a significant decline from its 52-week high, reflecting uncertainty in the data intelligence market. Investors are keenly awaiting the upcoming Q1 2026 earnings report to gauge the company's future performance.",
        "sentiment_score": 0.103707,
        "sentiment_label": "Neutral",
        "relevance_score": 0.637745,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Revvity’s IGRA Growth Engine Faces Crucial Test—Can It Offset Eroding China and Immunodiagnostics Headwinds?",
        "url": "https://www.bitget.com/news/detail/12560605360628",
        "date": "2026-04-11",
        "summary": "Revvity is facing a critical juncture where the growth from its Interferon-Gamma Release Assay (IGRA) testing segment needs to counteract the declining revenues from the China market and its Immunodiagnostics segment. The market has already priced in strong performance, suggesting that a mere beat on earnings might not drive significant stock rallies. The upcoming earnings call will be crucial for management to provide forward-looking signals and strong full-year guidance to justify the stock's ",
        "sentiment_score": -0.209244,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.382,
          "confidence": 0.38
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Revvity to Hold Earnings Call on Tuesday, May 5, 2026",
        "url": "https://www.marketscreener.com/news/revvity-to-hold-earnings-call-on-tuesday-may-5-2026-ce7e50d8d08ff626",
        "date": "2026-04-10",
        "summary": "Revvity, Inc. (NYSE: RVTY) announced it will release its first-quarter 2026 financial results before market open on Tuesday, May 5, 2026. The company will host a conference call at 7:30 a.m. ET on the same day to discuss these results, with President and CEO Prahlad Singh and CFO Max Krakowiak leading the call. A live audio webcast will be available on the Investors section of Revvity's website.",
        "sentiment_score": 0.032883,
        "sentiment_label": "Neutral",
        "relevance_score": 0.305454,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Revvity Schedules Q1 2026 Earnings Call",
        "url": "https://nationaltoday.com/us/ma/waltham/news/2026/04/10/revvity-to-hold-earnings-call-on-tuesday/",
        "date": "2026-04-10",
        "summary": "Revvity, Inc., a Waltham-based biotech company, announced it will release its first quarter 2026 financial results before the market opens on Tuesday, May 5, 2026. The company will also host a conference call at 7:30 a.m. ET on the same day to discuss these results. This report is crucial for investors as it provides updates on Revvity's financial performance and product pipeline.",
        "sentiment_score": 0.143488,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Revvity’s May 5 financial results will confirm the updated outlook—or could prompt a reassessment.",
        "url": "https://www.bitget.com/amp/news/detail/12560605355781",
        "date": "2026-04-10",
        "summary": "Revvity is nearing a critical juncture with its May 5 earnings report, which will determine if the company can sustain its ambitious 2026 financial projections and justify its high share valuation. Investors and analysts are closely watching, as a 'Hold' consensus rating and limited upside potential indicate a market that expects flawless execution. The upcoming results will serve as the first major test of the company's increased full-year guidance since its strong Q4 2025 performance, with any",
        "sentiment_score": -0.118207,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Revvity to Hold Earnings Call on Tuesday, May 5, 2026",
        "url": "https://www.businesswire.com/news/home/20260410482955/en/Revvity-to-Hold-Earnings-Call-on-Tuesday-May-5-2026",
        "date": "2026-04-10",
        "summary": "Revvity, Inc. (NYSE: RVTY) announced it will release its first quarter 2026 financial results before market open on Tuesday, May 5, 2026. The company will host a conference call at 7:30 a.m. ET on the same day to discuss these results, led by President and CEO Prahlad Singh and CFO Max Krakowiak. A live audio webcast will be available on Revvity's Investors section website.",
        "sentiment_score": 0.149739,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Revvity to Hold Earnings Call on Tuesday, May 5, 2026",
        "url": "https://markets.financialcontent.com/stocks/article/bizwire-2026-4-10-revvity-to-hold-earnings-call-on-tuesday-may-5-2026",
        "date": "2026-04-10",
        "summary": "Revvity, Inc. announced it will release its first quarter 2026 financial results before market open on Tuesday, May 5, 2026. The company will host a conference call on the same day at 7:30 a.m. ET to discuss these results, with President and CEO Prahlad Singh and CFO Max Krakowiak. A live audio webcast will be available on the Investors section of Revvity's website.",
        "sentiment_score": 0.062904,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Revvity unveils Signals BioDesign offering",
        "url": "https://www.tipranks.com/news/the-fly/revvity-unveils-signals-biodesign-offering-thefly-news-2",
        "date": "2026-04-10",
        "summary": "Revvity's Signals Software business has launched Signals BioDesign, a new cloud-native molecular cloning solution aimed at streamlining biologics research workflows. The platform is designed for biotech and pharma R&D teams, offering a collaborative digital environment that simplifies complex cloning processes and addresses the limitations of existing tools. This new offering combines essential cloning methodologies with enterprise-grade collaboration features.",
        "sentiment_score": 0.292661,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Revvity unveils Signals BioDesign offering",
        "url": "https://www.tipranks.com/news/the-fly/revvity-unveils-signals-biodesign-offering-thefly-news?mod=mw_quote_news",
        "date": "2026-04-10",
        "summary": "Revvity's Signals Software business has launched Signals BioDesign, a new cloud-native molecular cloning solution aimed at streamlining biologics research workflows. This platform is designed for biotech and pharma R&D teams to simplify complex cloning processes, enable scalable collaboration, and offer a unified digital environment. It distinguishes itself by combining essential cloning methodologies with enterprise-grade collaboration, addressing limitations found in traditional desktop tools ",
        "sentiment_score": 0.317873,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Revvity Launches Signals BioDesign Offering for Biologics Research Workflows",
        "url": "https://www.marketscreener.com/news/revvity-launches-signals-biodesign-offering-for-biologics-research-workflows-ce7e50d8d980f72d",
        "date": "2026-04-09",
        "summary": "Revvity has introduced Signals BioDesign, a new solution aimed at enhancing biologics research workflows. The offering is designed to streamline the discovery and development process of biological therapies. This launch comes amidst recent analyst adjustments to Revvity's price targets, reflecting ongoing market interest in the company's innovations.",
        "sentiment_score": 0.297384,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 0.997891,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Revvity (RVTY) Introduces New Cloud-Based Molecular Cloning Platform",
        "url": "https://www.gurufocus.com/news/8784664/revvity-rvty-introduces-new-cloudbased-molecular-cloning-platform",
        "date": "2026-04-09",
        "summary": "Revvity (RVTY) has launched Signals BioDesign, a new cloud-based platform aimed at enhancing molecular cloning in biologics research for biotech and pharmaceutical companies. While this innovation positions Revvity well, the company faces financial challenges including declining revenue and earnings growth, moderate leverage, and a \"grey area\" Altman Z-Score, indicating investor caution despite a high institutional ownership.",
        "sentiment_score": 0.055052,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Up to 1,000 constructs in one app: Revvity debuts cloud cloning tool",
        "url": "https://www.stocktitan.net/news/RVTY/revvity-unveils-its-signals-bio-design-offering-to-advance-biologic-surplmrcuzi3.html",
        "date": "2026-04-09",
        "summary": "Revvity, Inc. has launched Signals BioDesign, a cloud-native molecular cloning platform aimed at streamlining biologics research workflows for biotech and pharma R&D teams. This solution enables high-throughput construct design for up to 1,000 constructs, integrates with Revvity's Signals One platform, and supports various cloning methodologies. The cloud-native architecture offers enhanced collaboration, centralized data management, and is designed to accelerate therapeutic development and read",
        "sentiment_score": 0.416295,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Revvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows",
        "url": "https://www.businesswire.com/news/home/20260409192954/en/Revvity-Unveils-its-Signals-BioDesign-Offering-to-Advance-Biologic-Research-Workflows",
        "date": "2026-04-09",
        "summary": "Revvity Signals Software is launching Signals BioDesign, a new cloud-native molecular cloning solution designed to streamline biologics research workflows for biotech and pharma R&D teams. This platform simplifies complex cloning processes, enabling scalable, collaborative development in a unified digital environment. It supports various cloning methodologies, high-throughput construct design, and integrates with the Signals One platform, addressing limitations of existing tools and promoting AI",
        "sentiment_score": 0.420067,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Revvity Inc. stock outperforms competitors on strong trading day",
        "url": "https://www.marketwatch.com/data-news/revvity-inc-stock-outperforms-competitors-on-strong-trading-day-669e7888-6dedcba0c3a5?mod=mw_quote_news",
        "date": "2026-04-08",
        "summary": "Revvity Inc. (RVTY) shares rose 2.97% to $90.40 on Wednesday, outperforming the broader market. This gain ended a two-day losing streak for the company. The S&P 500 Index and Dow Jones Industrial Average also saw significant increases on the strong trading day.",
        "sentiment_score": 0.409296,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.711,
          "confidence": 0.71
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Revvity Sees Growth in Diagnostics, Encounters Challenges in China",
        "url": "https://www.bitget.com/amp/news/detail/12560605341295",
        "date": "2026-04-06",
        "summary": "Revvity (RVTY) is experiencing growth in its diagnostics and high-margin Signals Software segments, positioning it for expansion despite some short-term challenges. The company faces headwinds from reimbursement changes in China, subdued demand from academic and government sectors, and macroeconomic fluctuations, which have led to an underperformance in its stock this year. However, Revvity anticipates an average annual growth rate of 8.7% over the next five years, driven by its strong product l",
        "sentiment_score": -0.138704,
        "sentiment_label": "Neutral",
        "relevance_score": 0.970675,
        "sentiment": {
          "label": "positive",
          "score": 0.44,
          "confidence": 0.44
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Revvity Gains on Diagnostics Strength, Faces China Headwinds",
        "url": "https://www.tradingview.com/news/zacks:2d360ac63094b:0-revvity-gains-on-diagnostics-strength-faces-china-headwinds/",
        "date": "2026-04-06",
        "summary": "Revvity (RVTY) is experiencing growth due to its robust diagnostics segment, particularly in newborn screening and immunodiagnostics, and the expansion of its high-margin Signals Software business. However, the company faces headwinds in China due to reimbursement reforms impacting immunodiagnostics and weak academic/government demand in instrumentation, leading to a cautious growth outlook for 2026. While the Life Sciences segment shows signs of stabilization, margin pressures from tariffs, for",
        "sentiment_score": -0.109924,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.681,
          "confidence": 0.68
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Friedland Enterprises Files Amended Schedule 13D on Lulu's Fashion Lounge Holdings (LVLU), Publishes Independent FY2026 Financial Model",
        "url": "https://www.manilatimes.net/2026/04/06/tmt-newswire/globenewswire/friedland-enterprises-files-amended-schedule-13d-on-lulus-fashion-lounge-holdings-lvlu-publishes-independent-fy2026-financial-model/2314827",
        "date": "2026-04-06",
        "summary": "Friedland Enterprises has filed an amended Schedule 13D concerning its 5% stake in Lulu's Fashion Lounge Holdings (LVLU), acknowledging recent operational progress by the company. The activist investor has revised its six-point shareholder reform platform and published an independent FY2026 financial model, projecting revenue and Adjusted EBITDA scenarios for LVLU, which it believes is significantly undervalued.",
        "sentiment_score": 0.10424,
        "sentiment_label": "Neutral",
        "relevance_score": 0.626006,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Evercore Maintains Revvity(RVTY.US) With Buy Rating, Cuts Target Price to $108",
        "url": "https://www.moomoo.com/news/post/67925657/evercore-maintains-revvity-rvtyus-with-buy-rating-cuts-target-price",
        "date": "2026-04-06",
        "summary": "Evercore has reiterated its Buy rating for Revvity (RVTY.US) but has reduced the target price for the company's stock to $108. This adjustment indicates a continued positive outlook on the stock's potential despite a revision in its valuation.",
        "sentiment_score": 0.131422,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Revvity Sees Growth in Diagnostics, Encounters Challenges in China",
        "url": "https://www.bitget.com/news/detail/12560605341295",
        "date": "2026-04-06",
        "summary": "Revvity, Inc. (RVTY) is experiencing growth in its diagnostics sector and robust performance from its high-margin Signals Software segment. However, the company faces significant challenges, particularly in China due to reimbursement changes, which have led to a projected decline in immunodiagnostics in the region. Despite these headwinds and conservative growth projections for 2026, analysts anticipate an upward trend in earnings per share, with increased revenue and EPS expected for Q1 2026.",
        "sentiment_score": 0.122512,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.44,
          "confidence": 0.44
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Tudor Investment Corp ET AL Purchases Shares of 172,601 Revvity Inc. $RVTY",
        "url": "https://www.marketbeat.com/instant-alerts/filing-tudor-investment-corp-et-al-purchases-shares-of-172601-revvity-inc-rvty-2026-04-05/",
        "date": "2026-04-05",
        "summary": "Tudor Investment Corp ET AL has initiated a new position in Revvity Inc. (NYSE:RVTY), acquiring 172,601 shares valued at approximately $15.13 million. This purchase represents about 0.15% of the company, with institutional investors now holding 86.65% of the stock. Revvity recently surpassed quarterly earnings expectations and issued a positive full-year 2026 EPS guidance, while analysts currently hold a consensus \"Hold\" rating with a $112.92 price target.",
        "sentiment_score": 0.300988,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "VolitionRx Limited (AMEX:VNRX) Q4 2025 Earnings Call Transcript",
        "url": "https://www.insidermonkey.com/blog/volitionrx-limited-amexvnrx-q4-2025-earnings-call-transcript-1731677/",
        "date": "2026-04-04",
        "summary": "VolitionRx Limited (AMEX:VNRX) reported strong Q4 and full-year 2025 results, with 40% revenue growth driven by its Nu.Q Discover platform and initial sales of Nu.Q NETs products. The company highlighted significant progress in commercializing its Nu.Q platform for human diagnostics, including partnerships with Werfen and Hologic, and critical advancements in feline cancer detection and a novel Capture-Seq technology for pure circulating tumor DNA. VolitionRx is shifting its strategic focus from",
        "sentiment_score": 0.303405,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 0.710822,
        "sentiment": {
          "label": "negative",
          "score": -0.226,
          "confidence": 0.23
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Revvity (RVTY) Valuation Check After Recent Share Price Gains And Mixed Longer Term Returns",
        "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rvty/revvity/news/revvity-rvty-valuation-check-after-recent-share-price-gains/amp",
        "date": "2026-04-03",
        "summary": "Revvity (RVTY) has seen recent share price gains of 1.2% daily, despite a weaker longer-term performance with an 11.5% decline over the past year. One analyst target suggests the stock is undervalued by about 34% at $88.94, with a fair value estimate of $119.56, driven by expected margin expansion from product mix shifts and cost actions. However, its current P/E ratio of 41.5x is higher than the industry average, raising questions about whether expectations are already priced in, alongside pote",
        "sentiment_score": 0.279052,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.557,
          "confidence": 0.56
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Revvity, Inc. (RVTY) stock price, news, quote and history",
        "url": "https://uk.finance.yahoo.com/quote/RVTY/",
        "date": "2026-04-03",
        "summary": "This Yahoo Finance page provides comprehensive financial information for Revvity, Inc. (RVTY), including its current stock price, dividend announcements, historical performance data, and key metrics. It also offers an overview of the company's health sciences solutions, its market position in diagnostics and research, and analyst insights. The page enables users to compare RVTY with similar companies in the Diagnostics & Research industry.",
        "sentiment_score": 0.218226,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Revvity Inc. stock outperforms competitors on strong trading day",
        "url": "https://www.marketwatch.com/data-news/revvity-inc-stock-outperforms-competitors-on-strong-trading-day-864b9196-90099cfd2144?mod=mw_quote_news&gaa_at=eafs&gaa_n=AWEtsqdAICIXUryrWynDEwq_xdRAKBvdQYVik-eogmrzCxCHDSY7ZNzWGuO8&gaa_ts=69cf1686&gaa_sig=fa1p5qAR_9R1YOAZfnXZt3UTs9r2coJx3PKauYcq9X4n3uOrvzfZqwQ1g_VWI0h86Fzmhojw31WVhLut5WRsSg%3D%3D",
        "date": "2026-04-02",
        "summary": "Revvity Inc. (RVTY) saw its stock rise by 1.16% on Thursday, closing at $88.94. This performance outpaced the broader market, as the S&P 500 Index gained 0.11% while the Dow Jones Industrial Average declined by 0.13%. This marks Revvity's fourth consecutive day of stock gains.",
        "sentiment_score": 0.480821,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.711,
          "confidence": 0.71
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Baird Maintains Revvity (RVTY) Outperform Recommendation",
        "url": "http://www.msn.com/en-us/money/topstocks/baird-maintains-revvity-rvty-outperform-recommendation/ar-AA1PoAth?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1",
        "date": "2026-04-02",
        "summary": "This article states that Baird has maintained its \"Outperform\" recommendation for Revvity (RVTY). It does not provide any further details or analysis regarding this recommendation.",
        "sentiment_score": 0.368939,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Here’s Artisan Mid Cap Value Fund’s Investment Thesis for Revvity (RVTY)",
        "url": "https://www.insidermonkey.com/blog/heres-artisan-mid-cap-value-funds-investment-thesis-for-revvity-rvty-1729959/",
        "date": "2026-04-01",
        "summary": "Artisan Mid Cap Value Fund, in its fourth-quarter 2025 investor letter, highlighted its investment in Revvity, Inc. (NYSE: RVTY), a life sciences and diagnostics company. The fund's thesis focuses on Revvity's streamlined structure post-spin-off from PerkinElmer, high recurring revenue, and strong growth prospects, particularly within its BioLegend reagents and Signals software platform. Despite recent stock losses, Artisan views Revvity as an attractive risk-reward opportunity due to its discou",
        "sentiment_score": 0.417262,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.34,
          "confidence": 0.34
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Liquidity Mapping Around (RVTY) Price Events",
        "url": "https://news.stocktradersdaily.com/news_release/39/Liquidity_Mapping_Around_RVTY_Price_Events_040126084601_1775047561.html",
        "date": "2026-04-01",
        "summary": "This article, published on April 1, 2026, analyzes Revvity Inc. (NASDAQ: RVTY) using AI models, highlighting a weak near-term sentiment despite an exceptional 37.6:1 risk-reward setup. It outlines three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also provides multi-timeframe signal strengths with corresponding support and resistance levels for RVTY.",
        "sentiment_score": -0.171739,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Revvity CEO Acknowledges Challenges In Immunodiagnostics Business In China: Retail Terms Stock Drop An ‘Overreaction’",
        "url": "http://www.msn.com/en-us/money/companies/revvity-ceo-acknowledges-challenges-in-immunodiagnostics-business-in-china-retail-terms-stock-drop-an-overreaction/ar-AA1Js7st?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1",
        "date": "2026-04-01",
        "summary": "Revvity's CEO acknowledged challenges in the immunodiagnostics business in China, but attributed the stock drop to an overreaction by retail investors. This suggests the company is facing headwinds in a key market, potentially impacting future performance, while management seeks to reassure investors about its long-term prospects despite the short-term volatility.",
        "sentiment_score": -0.244719,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.202,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Revvity CEO Acknowledges Challenges In Immunodiagnostics Business In China: Retail Terms Stock Drop An ‘Overreaction’",
        "url": "https://www.msn.com/en-us/money/companies/revvity-ceo-acknowledges-challenges-in-immunodiagnostics-business-in-china-retail-terms-stock-drop-an-overreaction/ar-AA1Js7st?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1",
        "date": "2026-04-01",
        "summary": "Revvity's CEO, Prahlad Singh, acknowledged significant challenges in the company's immunodiagnostics business in China, attributing them to continued pricing pressure and slower than expected recovery. Despite the CEO's concerns, an analyst from William Blair views the subsequent 10% stock drop as an overreaction, maintaining an \"Outperform\" rating for the stock. This suggests a belief that the market's reaction to the news might be disproportionate to the actual long-term impact on the company.",
        "sentiment_score": 0.026481,
        "sentiment_label": "Neutral",
        "relevance_score": 0.344212,
        "sentiment": {
          "label": "negative",
          "score": -0.202,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Parkwalk leads $3.8m investment in Cavendish Laboratory spin-out Semarion",
        "url": "https://www.businessweekly.co.uk/posts/parkwalk-leads-38m-investment-in-cavendish-laboratory-spin-out-semarion",
        "date": "2026-03-31",
        "summary": "University of Cambridge spin-out Semarion has secured $3.8 million in funding, led by Parkwalk, to expand and scale manufacturing of its SemaCyte® platform. This platform enables the use of adherent cell models as assay-ready, barcoded reagents, aiming to improve flexibility, data richness, and scalability in drug discovery. The investment will support Semarion's commercial growth and broader adoption of its technology within the pharmaceutical industry.",
        "sentiment_score": 0.327504,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 0.918422,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Revvity (NYSE:RVTY) Price Target Cut to $96.00 by Analysts at JPMorgan Chase & Co.",
        "url": "https://www.marketbeat.com/instant-alerts/revvity-nyservty-price-target-cut-to-9600-by-analysts-at-jpmorgan-chase-co-2026-03-31/",
        "date": "2026-03-31",
        "summary": "JPMorgan Chase & Co. analysts have cut their price target for Revvity (NYSE:RVTY) from $105.00 to $96.00, maintaining a \"neutral\" rating with a potential upside of 11.61%. Despite this, the stock has a consensus \"Hold\" rating from multiple analysts, with an average target price of $112.92. Revvity recently reported strong quarterly earnings, beating EPS estimates and setting optimistic FY2026 guidance.",
        "sentiment_score": -0.245608,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.273,
          "confidence": 0.27
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Revvity price target lowered to $96 from $105 at JPMorgan",
        "url": "https://www.tipranks.com/news/the-fly/revvity-price-target-lowered-to-96-from-105-at-jpmorgan-thefly-news?utm_source=edition.cnn.com&utm_medium=referral",
        "date": "2026-03-31",
        "summary": "JPMorgan has reduced its price target for Revvity (RVTY) from $105 to $96, while maintaining a Neutral rating on the shares. This adjustment comes as JPMorgan updated its models within the life science tools and diagnostics sector. The article also notes other recent analyst actions on Revvity, including an upgrade from Sell to Hold by Nephron Research and price target increases by Baird, TD Cowen, and Evercore ISI.",
        "sentiment_score": -0.402587,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.128,
          "confidence": 0.13
        }
      }
    ]
  }
}